MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.81
+0.39
+2.91%
After Hours: 13.81 0 0.00% 16:20 07/28 EDT
OPEN
14.28
PREV CLOSE
13.42
HIGH
14.32
LOW
12.90
VOLUME
694.40K
TURNOVER
--
52 WEEK HIGH
16.63
52 WEEK LOW
2.400
MARKET CAP
449.02M
P/E (TTM)
-19.5637
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 1d ago
74 Biggest Movers From Yesterday
Gainers
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 2d ago
48 Stocks Moving In Monday's Mid-Day Session
Gainers Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The stock is also trading higher in sympathy with the price of Bitcoin.
Benzinga · 2d ago
Stocks That Hit 52-Week Highs On Monday
    This morning 121 companies reached new 52-week highs.
Benzinga · 2d ago
Oramed Will Soon Start Clinical Trials For Oral COVID-19 Vaccine In Israel, Out licensed Injectable Version To Premas Biotech In India
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced several updates for its majority-owned company Oravax Medical Inc.
Benzinga · 07/21 15:44
Oramed subsidiary to start clinical trials for its oral COVID-19 vaccine candidate
ACELYA AKSUNKUR/iStock via Getty Images Announcing updates of its majority-owned company Oravax Medical, Oramed Pharmaceuticals (ORMP) said clinical trials for the unit’s oral COVID-19 vaccine would get underway first in
Seekingalpha · 07/21 13:28
BRIEF-Oramed - Oravax Gearing Up To Begin Clinical Trials For Oral Covid-19 Vaccine, First In Israel, Then In Additional Clinical Sites Internationally
reuters.com · 07/21 12:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORMP. Analyze the recent business situations of Oramed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORMP stock price target is 22.50 with a high estimate of 27.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 1.23M
% Owned: 3.78%
Shares Outstanding: 32.51M
TypeInstitutionsShares
Increased
17
275.87K
New
14
248.28K
Decreased
3
32.28K
Sold Out
8
515.29K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.51%
Pharmaceuticals & Medical Research
+1.92%
Key Executives
Chairman/Independent Director
Kevin Rakin
Chief Executive Officer/President/Director
Nadav Kidron
Chief Financial Officer/Treasurer/Secretary
David Silberman
Chief Operating Officer
Joshua Hexter
Chief Scientific Officer/Director
Miriam Kidron
Independent Director
Aviad Friedman
Independent Director
Xiaoming Gao
Independent Director
Arie Mayer
Independent Director
Leonard Sank
No Data
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.